4.5 Article

Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act

Related references

Note: Only part of the references are listed.
Article Neurosciences

Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease

Allison M. Bradbury et al.

EXPERIMENTAL NEUROLOGY (2015)

Editorial Material Clinical Neurology

Assessment of neurological and behavioural function: the NIH Toolbox

Richard C. Gershon et al.

LANCET NEUROLOGY (2010)

Article Clinical Neurology

Randomized, Controlled Trial of Miglustat in Gaucher's Disease Type 3

Raphael Schiffmann et al.

ANNALS OF NEUROLOGY (2008)

Article Pediatrics

Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease

Ozlem Goker-Alpan et al.

JOURNAL OF PEDIATRICS (2008)

Article Medicine, General & Internal

Does orphan drug legislation really answer the needs of patients?

Marlene E. Haffner et al.

LANCET (2008)

Article Clinical Neurology

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

Marc C. Patterson et al.

LANCET NEUROLOGY (2007)

Article Urology & Nephrology

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing

Raphael Schiffmann et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)

Article Endocrinology & Metabolism

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

Joseph Muenzer et al.

MOLECULAR GENETICS AND METABOLISM (2007)

Article Pediatrics

Pediatric Fabry disease

M Ries et al.

PEDIATRICS (2005)

Article Pediatrics

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

P Harmatz et al.

JOURNAL OF PEDIATRICS (2004)

Article Biochemistry & Molecular Biology

Prevalence of lysosomal storage diseases in Portugal

R Pinto et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2004)